FDA Issues New Warning for Two Diabetes Medications

Share this content:
FDA Issues New Warning for Two Diabetes Medications
FDA Issues New Warning for Two Diabetes Medications

WEDNESDAY, April 6, 2016 (HealthDay News) -- Diabetes medications containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, U.S. health officials warned Tuesday.

The FDA said its warning was based on results of two large trials done involving patients with heart disease. Both trials found that more patients taking drugs containing saxagliptin or alogliptin were hospitalized for heart failure than patients receiving a placebo.

In the saxagliptin trial, 3.5 percent of patients receiving the drug were hospitalized for heart failure, compared with 2.8 percent of patients receiving a placebo. Risk factors included a history of heart failure or kidney impairment, the FDA reported. In the alogliptin trial, 3.9 percent of patients taking the drug were hospitalized for heart failure, compared with 3.3 percent receiving a placebo.

The FDA said it's asking doctors to consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure. If blood glucose is not well-controlled with current treatments, other diabetes drugs may be needed, the agency said.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »